In 2023, obesity therapeutics research continued to evolve with some major advances and indications for anti-obesity medications. I will discuss the broadened evidence for semaglutide for obesity management in special populations, new evidence for incretin co-agonist therapy, including tirzepatide and retatrutide. Finally, I will discuss new molecules showing promise for obesity management.